Welcome to our dedicated page for Bioadaptives SEC filings (Ticker: BDPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Curious whether Bioadaptives’ next herbal cognitive enhancer is fully funded, or how much cash remains for upcoming trials? This SEC filings hub for Bioadaptives, Inc. (BDPT) puts every disclosure in context so you can locate answers fast.
Investors typically dive into three areas first: R&D spending trends, insider confidence, and capital raises. Our platform guides that journey. Open the latest 10-K annual report and you’ll find AI-generated notes that flag clinical-trial milestones, patent status and going-concern language—“Bioadaptives annual report 10-K simplified” in one click. Switch to the most recent 10-Q and compare quarter-over-quarter burn rate through our interactive charts, a feature purpose-built for anyone searching “Bioadaptives quarterly earnings report 10-Q filing”.
Need real-time alerts on management moves? Our system captures every Form 4 within minutes. Whether you search “Bioadaptives insider trading Form 4 transactions” or “Bioadaptives executive stock transactions Form 4”, you’ll see color-coded buys and sells, summarized in plain English. Material shifts like distributor agreements or product-trial results are tagged under 8-K with the label “Bioadaptives 8-K material events explained”.
Key page features include:
- AI-powered summaries that turn 200-page documents into concise briefs—perfect for “understanding Bioadaptives SEC documents with AI”.
- Real-time filing feeds directly from EDGAR, so “Bioadaptives Form 4 insider transactions real-time” is literally true.
- Side-by-side comparisons of proxy statements for anyone researching “Bioadaptives proxy statement executive compensation”.
- One-click trend charts for revenue, R&D expenses and share count—ideal for “Bioadaptives earnings report filing analysis”.
Stop paging through dense PDFs. Our AI surfaces the specifics—cash runway, product pipeline updates, dilution risk—so you can make informed decisions without the legwork.
BioAdaptives (BDPT) director filed a Form 4 reporting the acquisition of 1,382 shares of Series D Convertible Preferred Stock on 11/01/2025, issued as compensation for board services. The filing lists a $0 price for the derivative award.
Each Series D share is convertible into common stock at a 100:1 ratio, corresponding to 138,200 underlying common shares, subject to a 4.9% beneficial ownership limitation. The Series D shares become convertible six months after issuance (stated as 05/01/2026), with conversion occurring immediately in a liquidation scenario. Each Series D share carries 100 votes on matters of the issuer, and the right to convert does not expire.
Mark P. Frissora, a director of BioAdaptives, Inc. (BDPT), received compensation in the form of Series D Convertible Preferred Stock on
FAQ
What is the current stock price of Bioadaptives (BDPT)?
What is the market cap of Bioadaptives (BDPT)?
